

(57) Abstract: Intermediate compounds (i.e., oligonucleotide fragments) are disclosed for making RNAi agents, or pharmaceutically acceptable salts thereof. In addition, methods are disclosed for making single-stranded oligonucleotides by ligating two or more of the intermediate compounds herein via a hybrid chemical-enzymatic route.